Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Short term Debt (2019 - 2023)

Immunovant filings provide 4 years of Short term Debt readings, the most recent being $350000.0 for Q1 2023.

  • Quarterly Short term Debt rose 104.68% to $350000.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $350000.0 through Mar 2023, up 104.68% year-over-year, with the annual reading at $350000.0 for FY2023, 104.68% up from the prior year.
  • Short term Debt hit $350000.0 in Q1 2023 for Immunovant, up from $171000.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $5.0 million in Q2 2019 and bottomed at $58000.0 in Q1 2019.
  • Average Short term Debt over 4 years is $1.7 million, with a median of $350000.0 recorded in 2023.
  • Peak annual rise in Short term Debt hit 5400.0% in 2020, while the deepest fall reached 94.64% in 2020.
  • Immunovant's Short term Debt stood at $3.1 million in 2019, then plummeted by 95.72% to $134000.0 in 2020, then rose by 27.61% to $171000.0 in 2022, then soared by 104.68% to $350000.0 in 2023.
  • Per Business Quant, the three most recent readings for IMVT's Short term Debt are $350000.0 (Q1 2023), $171000.0 (Q1 2022), and $134000.0 (Q3 2020).